Xipere receives Category 1 CPT code
Click Here to Manage Email Alerts
Key takeaways:
- Xipere received a Category 1 CPT code.
- The new code and its descriptors will become effective Jan. 1, 2024.
The AMA has assigned a Category 1 CPT code for Xipere, according to a press release from Bausch + Lomb.
Xipere (triamcinolone acetonide injectable suspension), the first FDA-approved therapy for suprachoroidal use for the treatment of macular edema associated with uveitis, was launched in the U.S. in March 2022.
“The Category 1 code will help facilitate better access and adoption of Xipere and its unique suprachoroidal injection method, which enables targeted delivery of the medication,” Andrew Stewart, president, global pharmaceuticals and international consumer, Bausch + Lomb, said in the release. “We greatly appreciate the support and guidance AAO and ASRS provided throughout this process.”
The code and its descriptors will be added to a future version of the CPT Codebook and will become effective Jan. 1, 2024.
Read more about
Click Here to Manage Email Alerts